C1071003 MagnetisMM-3

  • STATUS
    Not Recruiting
  • participants needed
    150
Send
Updated on 14 January 2022
refractory multiple myeloma

Summary

The purpose of the study is to evaluate whether single-agent PF-06863135 can provide clinical benefit in participants with relapsed/refractory multiple myeloma. PF-06863135 is a bispecific antibody: binding of PF-06863135 to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.

Description


Details
Condition Neoplasms Hemostatic Disorders, Neoplasms by Histologic Type, Immunoproliferative Disorders, PF-06863135, BCMA, Hematologic Diseases, Lymphoproliferative Disorders, BCMA-CD3 bispecific, Neoplasms, Elranatamab, Blood Protein Disorders, Myeloma, bispecific, Plasma Cell, Vascular Diseases, Multiple Myeloma, Hemorrhagic Disorders, bispecific antibody, MagnetisMM-3, relapsed Multiple Myeloma, Cardiovascular Diseases, refractory Multiple Myeloma, Multiple Myeloma, Immune System Diseases, Paraproteinemias
Clinical Study IdentifierTX258544
Last Modified on14 January 2022

Similar trials to consider

Browse trials for

refractory multiple myeloma

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note